| scholarly article | Q13442814 |
| P356 | DOI | 10.1016/J.EURURO.2018.11.016 |
| P698 | PubMed publication ID | 30473431 |
| P50 | author | Hans-Jürgen Wester | Q128303541 |
| P2093 | author name string | Markus Schwaiger | |
| Margitta Retz | |||
| Wolfgang A Weber | |||
| Matthias Eiber | |||
| Robert Tauber | |||
| Calogero D'Alessandria | |||
| Matthias M Heck | |||
| Jürgen E Gschwend | |||
| Andrei Gafita | |||
| Tobias Maurer | |||
| Karina Knorr | |||
| Sebastian Schwaiger | |||
| P433 | issue | 6 | |
| P921 | main subject | lutetium-177 | Q18882670 |
| P304 | page(s) | 920-926 | |
| P577 | publication date | 2018-11-22 | |
| P1433 | published in | European Urology | Q15763991 |
| P1476 | title | Treatment Outcome, Toxicity, and Predictive Factors for Radioligand Therapy with 177Lu-PSMA-I&T in Metastatic Castration-resistant Prostate Cancer | |
| P478 | volume | 75 |
| Q90163212 | (Radio)Theranostic Patient Management in Oncology Exemplified by Neuroendocrine Neoplasms, Prostate Cancer, and Breast Cancer |
| Q91776832 | Current Status and Growth of Nuclear Theranostics in Singapore |
| Q92643925 | Expanding the role of small-molecule PSMA ligands beyond PET staging of prostate cancer |
| Q90598687 | Lutetium-177 prostate-specific membrane antigen (PSMA) theranostics: practical nuances and intricacies |
| Q92063519 | Metastatic extent predicts survival as patients with metastatic castration-resistant prostate cancer are treated with 177Lu-PSMA radioligand therapy |
| Q89529826 | Radiolabelled Peptides for Positron Emission Tomography and Endoradiotherapy in Oncology |
| Q92604860 | Second line chemotherapy and visceral metastases are associated with poor survival in patients with mCRPC receiving 177Lu-PSMA-617 |
| Q90481523 | Targeted alpha therapy in a systemic mouse model of prostate cancer - a feasibility study |
Search more.